Article

The SDF-1α/CXCR4 Axis is Required for Proliferation and Maturation of Human Fetal Pancreatic Endocrine Progenitor Cells

University of Bremen, Germany
PLoS ONE (Impact Factor: 3.53). 06/2012; 7(6):e38721. DOI: 10.1371/journal.pone.0038721
Source: PubMed

ABSTRACT The chemokine receptor CXCR4 and ligand SDF-1α are expressed in fetal and adult mouse islets. Neutralization of CXCR4 has previously been shown to diminish ductal cell proliferation and increase apoptosis in the IFNγ transgenic mouse model in which the adult mouse pancreas displays islet regeneration. Here, we demonstrate that CXCR4 and SDF-1α are expressed in the human fetal pancreas and that during early gestation, CXCR4 colocalizes with neurogenin 3 (ngn3), a key transcription factor for endocrine specification in the pancreas. Treatment of islet like clusters (ICCs) derived from human fetal pancreas with SDF-1α resulted in increased proliferation of epithelial cells in ICCs without a concomitant increase in total insulin expression. Exposure of ICCs in vitro to AMD3100, a pharmacological inhibitor of CXCR4, did not alter expression of endocrine hormones insulin and glucagon, or the pancreatic endocrine transcription factors PDX1, Nkx6.1, Ngn3 and PAX4. However, a strong inhibition of β cell genesis was observed when in vitro AMD3100 treatment of ICCs was followed by two weeks of in vivo treatment with AMD3100 after ICC transplantation into mice. Analysis of the grafts for human C-peptide found that inhibition of CXCR4 activity profoundly inhibits islet development. Subsequently, a model pancreatic epithelial cell system (CFPAC-1) was employed to study the signals that regulate proliferation and apoptosis by the SDF-1α/CXCR4 axis. From a selected panel of inhibitors tested, both the PI 3-kinase and MAPK pathways were identified as critical regulators of CFPAC-1 proliferation. SDF-1α stimulated Akt phosphorylation, but failed to increase phosphorylation of Erk above the high basal levels observed. Taken together, these results indicate that SDF-1α/CXCR4 axis plays a critical regulatory role in the genesis of human islets.

Download full-text

Full-text

Available from: Andrew Hinton, Jul 01, 2015
0 Followers
 · 
176 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Decreased β-cell mass is a hallmark of type 2 diabetes, and therapeutic approaches to increase the pancreatic β-cell mass have been expected. In recent years, gastrointestinal incretin peptides have been shown to exert a cell-proliferative effect in pancreatic β-cells. Trefoil factor 2 (TFF2), which is predominantly expressed in the surface epithelium of the stomach, plays a role in antiapoptosis, migration, and proliferation. The TFF family is expressed in pancreatic β-cells, whereas the role of TFF2 in pancreatic β-cells has been obscure. In this study, we investigated the mechanism by which TFF2 enhances pancreatic β-cell proliferation. The effects of TFF2 on cell proliferation were evaluated in INS-1 cells, MIN6 cells, and mouse islets using an adenovirus vector containing TFF2 or a recombinant TFF2 peptide. The forced expression of TFF2 led to an increase in bromodeoxyuridine (BrdU) incorporation in both INS-1 cells and islets, without any alteration in insulin secretion. TFF2 significantly increased the mRNA expression of cyclin A2, D1, D2, D3, and E1 in islets. TFF2 peptide increased ERK1/2 phosphorylation and BrdU incorporation in MIN6 cells. A MAPK kinase inhibitor (U0126) abrogated the TFF2 peptide-mediated proliferation of MIN6 cells. A CX-chemokine receptor-4 antagonist also prevented the TFF2 peptide-mediated increase in ERK1/2 phosphorylation and BrdU incorporation in MIN6 cells. These results indicated that TFF2 is involved in β-cell proliferation at least partially via CX-chemokine receptor-4-mediated ERK1/2 phosphorylation, suggesting TFF2 may be a novel target for inducing β-cell proliferation.
    Endocrinology 11/2012; 154(1). DOI:10.1210/en.2012-1814 · 4.64 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Islet transplantation-based therapies were proven successful for type 1 diabetes mellitus, but an extreme shortage of pancreatic islets has motivated recent efforts to develop renewable sources of islet-replacement tissue. Pancreatic progenitor cells hold a promising potential, yet attempts at their prospective isolation are scarce due to the lack of specific marker. We found that prominin-1 (often referred to as CD133 in humans) is expressed by the undifferentiated epithelial cells in the mouse embryonic pancreas. Putative pancreatic epithelial stem and progenitor cells were prospectively enriched in prominin-1(+) cell population by cell sorting and characterized. CD133 is also a cell surface marker of human pancreatic cancer stem cells (CSC), which are resistant to conventional treatments such as chemotherapy and radiotherapy. Therefore, a considerable interest in the specific targeting and eradication of CSC is emerging for the cancer therapy, and CD133 may represent a good molecular target. In this chapter, I will summarize our current knowledge about prominin-1/CD133 in mouse and human pancreas.
    Advances in Experimental Medicine and Biology 01/2013; 777:185-96. DOI:10.1007/978-1-4614-5894-4_12 · 2.01 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Hyperglycemia in chemical-induced diabetic mice has been reported to alleviate after bone marrow transplantation. Nevertheless, the underlying mechanism remains elusive. In the present study, genetically labeled primary mouse mesenchymal stem cells were grafted into the pancreas of isogeneic mice that had developed hyperglycemia by injection of streptozotocin, a beta-cell specific toxin. We found that the blood glucose levels of the mice that received mesenchymal stem cells significantly decreased, resulting from a recovery in beta cell mass. Further analysis revealed that the increase in beta cell mass was predominantly attributable to beta cell replication. The grafted mesenchymal stem cells did not transdifferentiate into beta cells themselves but recruited and polarized macrophages in a Stromal cell-derived factor 1-dependent manner, which in turn promoted beta cell replication. Our finding thus suggests that transplantation of autogenic mesenchymal stem cells may boost endogenous beta cell replication in diabetes patients.
    The international journal of biochemistry & cell biology 11/2013; 53. DOI:10.1016/j.biocel.2013.10.012 · 4.24 Impact Factor